Medicenna Therapeutics Corp. (OTC:MDNAF) Stock In Focus After Recent News

This morning, most investors are going to focus on companies that were in the news cycle this past Friday, and one of the companies that could be worth tracking is Medicenna Therapeutics Corp. (OTC:MDNAF). The company is an immunotherapy operator focused on developing superkines. On January 12, the company announced the appointment of a new auditor in the form of MNP LLP. Additionally, it was also announced that Medicenna Therapeutics had accepted the resignation of its former auditors, PriceWaterhouseCoopers LLP.

MNP LLP had been appointed in the role up until the subsequent annual general meeting of Medicenna Therapeutics. In the news release from the company last Friday, it was noted that there had been no modified opinions or reservations about the reports composed by the former auditor in the two most recent fiscal years. The members of the company’s board of directors as well as those of its audit committee had approved the resignation of PriceWaterhouseCoopers and the subsequent appointment of MNP LLP.

The company also noted that there were no’reportable events’ in line with the definition of National Instrument 51-102, Continuous Disclosure Obligations, in the past two audits by the former auditor. Those audits had taken place prior to the tendering of the resignation. The requisite notices of change pertaining to the auditor had also been approved by the Board of Directors.

However, that was not all. Medicenna Therapeutics also announced that it had engaged the services of Tandem Accounting Group Ltd. for the purpose of managing the financial reporting and internal bookkeeping of the company. It was another significant announcement from the company. In the news release, Medicenna Therapeutics also noted that Tandem Accounting was led by a highly experienced team of professionals. It could be a good idea to keep an eye on the stock.